R&D

Adequate levels of vitamin D reduces complications, death among COVID-19 patients

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a significant decreased risk for adverse clinical outcomes including becoming unconscious, hypoxia (body starved for oxygen) and death.

Boost for global response to COVID-19 as economies worldwide formally sign up to COVAX facility

64 higher income economies have joined the COVAX Facility, a global initiative that brings together governments and manufacturers to ensure eventual COVID-19 vaccines reach those in greatest need, whoever they are and wherever they live. These 64 economies include commitments from 35 economies as well as the European Commission which will procure doses on behalf of 27 EU member states plus Norway and Iceland.

T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity

Ever since SARS-CoV-2 first appeared, researchers have been trying to understand whether sometimes the immune system does more harm than good during the acute phase of COVID-19. The latest study by researchers at La Jolla Institute for Immunology clearly argues in favor of the immune system.

Designed antiviral proteins inhibit SARS-CoV-2 in the lab

Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19.

In the experiments, the lead antiviral candidate, named LCB1, rivaled the best-known SARS-CoV-2 neutralizing antibodies in its protective actions. LCB1 is currently being evaluated in rodents.

Tiny antibody component highly effective against SARS-COV-2 in animal studies

University of Pittsburgh School of Medicine scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is the cause of COVID-19. This antibody component, which is 10 times smaller than a full-sized antibody, has been used to construct a drug - known as Ab8 - for potential use as a therapeutic and prophylactic against SARS-CoV-2.

Which immune response could cause a vaccine against COVID-19?

Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition. It is especially important now when multiple vaccines against COVID-19 are being developed. The top immunologists analyse types of immune response to predict what kind of vaccine would be the best.

COVID-19 study links strict social distancing to much lower chance of infection

Using public transportation, visiting a place of worship, or otherwise traveling from the home is associated with a significantly higher likelihood of testing positive with the coronavirus SARS-CoV-2, while practicing strict social distancing is associated with a markedly lower likelihood, suggests a study from researchers at the Johns Hopkins Bloomberg School of Public Health.

Research & Development

Adequate levels of vitamin D reduces complications, death among COVID-19 patients

Boost for global response to COVID-19 as economies worldwide formally sign up to COVAX facility

T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity

Designed antiviral proteins inhibit SARS-CoV-2 in the lab

Tiny antibody component highly effective against SARS-COV-2 in animal studies

Which immune response could cause a vaccine against COVID-19?

COVID-19 study links strict social distancing to much lower chance of infection

More Pharma News ...